Ischemia-induced cleavage of cadherins in NRK cells requires MT1-MMP (MMP-14)

Department of Medical Pharmacology and Toxicology, College of Medicine, Texas A&M University System Health Science Center, College Station, Texas, USA.
American journal of physiology. Renal physiology (Impact Factor: 3.25). 02/2006; 290(1):F43-51. DOI: 10.1152/ajprenal.00179.2005
Source: PubMed


Ischemia is a leading cause of acute renal failure (ARF), a disease associated with high morbidity and mortality. Disruption of intercellular adhesion in the proximal tubules is linked to ARF, although the molecular mechanism(s) remains unclear. Our previous studies showed that ischemia is associated with cadherin cleavage and loss in NRK cells, putatively due to a matrix metalloproteinase (MMP) (7). In the current studies, a MMP required for E-cadherin cleavage and N-cadherin loss was identified. Chemical inhibitors against a number of soluble MMPs (1, 2, 3, 8, 9) failed to completely attenuate ischemia-induced cadherin loss. Under ischemic conditions, there was an increase in active membrane-type (MT)1-MMP but a decrease in MMP-2 protein expression. Plating cells on fibronectin protected against ischemia-induced loss of cadherins and, interestingly, no increase in active MT1-MMP levels was seen in ischemic cells on fibronectin-coated dishes. In addition, L cells stably expressing E- (LE) or N-cadherin (LN), but lacking MT1-MMP expression, were resistant to ischemia-induced cadherin loss. The role of MT1-MMP in ischemia-induced cadherin loss was confirmed by either blocking MT1-MMP activity with a neutralizing antibody or expression with shRNA constructs which protected full-length E- and N-cadherin during ischemia. Using shRNA constructs to suppress MT1-MMP expression, ischemia-induced disruption of cadherin function was ablated, and cell-cell contacts were preserved. These results demonstrate that ischemia induces increased expression of active MT1-MMP and subsequent disruption of cadherin/catenin complexes, implying that MT1-MMP plays a role in ischemia-induced ARF.

1 Follower
7 Reads
  • Source
    • "Primary differentiated EOC display abundant expression of the cell-cell junctional protein E-cadherin; however, reduced E-cadherin staining is found in late-stage carcinomas and data suggest that loss of E-cadherin expression or function is a factor in EOC progression from well-differentiated lesions to poorly differentiated tumors and metastases [2–4]. As matrix metalloproteinases (MMPs) are implicated in E-cadherin ectodomain shedding [23–26] and LPA is linked to altered MMP expression [12–14], the current study was designed to evaluate a potential functional link between LPA, posttranslational regulation of E-cadherin function, and epithelial cohesion in EOC. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Ovarian cancer metastasizes via exfoliation of free-floating cells and multicellular aggregates from the primary tumor to the peritoneal cavity. A key event in EOC metastasis is disruption of cell-cell contacts via modulation of intercellular junctional components including cadherins. Ascites is rich in lysophosphatidic acid (LPA), a bioactive lipid that may promote early events in ovarian cancer dissemination. The objective of this paper was to assess the effect of LPA on E-cadherin junctional integrity. We report a loss of junctional E-cadherin in OVCAR3, OVCA429, and OVCA433 cells exposed to LPA. LPA-induced loss of E-cadherin was concentration and time dependent. LPA increased MMP-9 expression and promoted MMP-9-catalyzed E-cadherin ectodomain shedding. Blocking LPA receptor signaling inhibited MMP-9 expression and restored junctional E-cadherin staining. LPA-treated cells demonstrated a significant decrease in epithelial cohesion. Together these data support a model wherein LPA induces MMP-9 expression and MMP-9-catalyzed E-cadherin ectodomain shedding, resulting in loss of E-cadherin junctional integrity and epithelial cohesion, facilitating metastatic dissemination of ovarian cancer cells.
    Journal of Oncology 04/2012; 2012(10):501492. DOI:10.1155/2012/501492
  • Source
    • "Our data is contradictory to previous results which have revealed MMPs as major contributors to the control of paracellular permeability by proteolytic degradation of TJ proteins. More specifically, MMPs have been correlated with an increase in capillary permeability that follows ischemia-reperfusion injury in brain [8], in myocardium [4], in lung [21] and in kidney [22]. These studies attributed to MMPs an elementary role in the inflammatory process and the breakdown of the paracellular capillary permeability during inflammation. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Matrix metalloproteinases (MMPs) 2 and 9 are two gelatinase members which have been found elevated in exudative pleural effusions. In endothelial cells these MMPs increase paracellular permeability via the disruption of tight junction (TJ) proteins occludin and claudin. In the present study it was investigated if MMP2 and MMP9 alter permeability properties of the pleura tissue by degradation of TJ proteins in pleural mesothelium. In the present study the transmesothelial resistance (RTM) of sheep pleura tissue was recorded in Ussing chambers after the addition of MMP2 or MMP9. Both enzymes reduced RTM of the pleura, implying an increase in pleural permeability. The localization and expression of TJ proteins, occludin and claudin-1, were assessed after incubation with MMPs by indirect immunofluorescence and western blot analysis. Our results revealed that incubation with MMPs did not alter neither proteins localization at cell periphery nor their expression. MMP2 and MMP9 increase the permeability of sheep pleura and this finding suggests a role for MMPs in pleural fluid formation. Tight junction proteins remain intact after incubation with MMPs, contrary to previous studies which have shown TJ degradation by MMPs. Probably MMP2 and MMP9 augment pleural permeability via other mechanisms.
    BMC Physiology 03/2012; 12(1):2. DOI:10.1186/1472-6793-12-2
  • Source
    • "sE-cadherin is a form, cleaved from E-cadherin by proteases such as MMP-3, MMP-7 [10], plasmin [11], ADAM10 [12], ADAM15 [13], whereas sN-CAD is cleaved by ADAM10 [14], MT1-MMP [15], MT5-MMP [16], MMP-9, MMP-12 [17], and Presenilin 1 [18]. The induction/upregulation of various MMPs (e.g. "
    [Show abstract] [Hide abstract]
    ABSTRACT: An increasing number of publications are suggesting that galectin-3 (Gal-3) and soluble cadherin fragments, such as E-cadherin (sE-CAD) and N-cadherin (sN-CAD), may be considered as cancer markers. Despite the promising results of the studies, there are no data concerning their levels in the plasma of echinococcosis patients. In most cases, echinoccocosis affects the liver, and its symptoms and disease course are very similar to those of liver cancer. The aim of the present study was to observe whether echinococcosis affects the concentration of soluble sN-CAD, sE-CAD fragments and Gal-3 in plasma and to determine which of them could be considered reliable liver cancer markers for further research. The concentrations of sN-CAD, sE-CAD and Gal-3 in the EDTA plasma of patients suffering from echinococcosis (N = 20), liver cancers (N = 10) and healthy subjects (N = 20) were measured using the ELISA method. The plasma concentration of sE-CAD was lower (p = 0.0381), and that of Gal-3 higher (p = 0.0288), in echinococcosis than in the healthy group. However, only the concentration of sE-CAD differed significantly among the three analysed groups. In echinococcosis there was a correlation between the sE-CAD and CRP levels (rs = 0.79; p = 0.0066) as well as a correlation between the sE-CAD level and the number of leukocytes (rs = 0.65; p = 0.0210) in the blood. Echinococcosis affects the concentration of soluble sE-CAD fragments and Gal-3 in plasma. sE-CAD can be considered as a marker for differentiation between liver cancer and echinoccocossis, a parasitic liver disease similar in symptoms. Further study is required to confirm these preliminary results. VIRTUAL SLIDES: The virtual slide(s) for this article can be found here:
    Diagnostic Pathology 02/2012; 7(1):17. DOI:10.1186/1746-1596-7-17 · 2.60 Impact Factor
Show more

Similar Publications